Tsubota Laboratory Incorporated (JP:4890)
:4890
Want to see JP:4890 full AI Analyst Report?
4890 Stock Chart & Stats
¥340.00
¥1.00(0.24%)
At close: 4:00 PM EST
¥340.00
¥1.00(0.24%)
Day’s Range― - ―
52-Week Range¥251.00 - ¥478.00
Previous CloseN/A
Volume43.10K
Average Volume (3M)31.02K
Market Cap
¥7.61B
Enterprise Value¥6.55B
Total Cash (Recent Filing)¥1.47B
Total Debt (Recent Filing)¥85.26M
Price to Earnings (P/E)―
Beta0.10
Next Earnings
May 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.22
Shares Outstanding25,794,300
10 Day Avg. Volume26,720
30 Day Avg. Volume31,016
Financial Highlights & Ratios
PEG Ratio-0.37
Price to Book (P/B)6.35
Price to Sales (P/S)7.43
P/FCF Ratio-30.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Robust Balance Sheet And Low LeverageA strong equity base and low leverage provide durable financial flexibility, allowing the company to fund R&D and commercialization without heavy interest burdens. This supports multi-quarter investment in product development and partnerships, reducing insolvency and refinancing risk over 2–6 months.
High Gross Margins And Improving Operating MarginsSustainably high gross margins and improving EBIT/EBITDA margins indicate structural cost advantages or pricing power in core products. This margin durability supports reinvestment and resilience to revenue swings, improving the firm's ability to fund growth and withstand industry cyclicality over the medium term.
IP-driven, Product And Licensing Revenue ModelA diversified commercial model—product sales, licensing royalties, and partner-funded development—creates multiple durable revenue levers. Licensing and collaborations can scale revenue without commensurate fixed costs, supporting long-term margins and lower capital intensity as products mature and partners commercialize.
Bears Say
Negative Operating And Free Cash FlowPersistent negative operating and free cash flow signal structural cash-generation weakness, forcing reliance on equity or financing for operations and R&D. Over several quarters this can constrain marketing, production scale-up, or partnership execution and raise liquidity risk if trends don't reverse.
Very Small Workforce And Limited ScaleA tiny employee base points to limited internal capacity to scale commercial operations, manage regulatory processes, or expand distribution. Dependence on partners or external contractors increases execution risk and could slow product rollouts or market penetration over the coming months.
Profit And Revenue VolatilityLarge swings in net profitability and uneven revenue trends reflect operational or demand variability and reduce predictability for investment planning. Volatility complicates partner negotiations and long-term contracts and raises the chance of repeated margin pressure if adverse events recur.
Tsubota Laboratory Incorporated News
4890 FAQ
What was Tsubota Laboratory Incorporated’s price range in the past 12 months?
Tsubota Laboratory Incorporated lowest stock price was ¥251.00 and its highest was ¥478.00 in the past 12 months.
What is Tsubota Laboratory Incorporated’s market cap?
Tsubota Laboratory Incorporated’s market cap is ¥7.61B.
When is Tsubota Laboratory Incorporated’s upcoming earnings report date?
Tsubota Laboratory Incorporated’s upcoming earnings report date is May 14, 2026 which is in 15 days.
How were Tsubota Laboratory Incorporated’s earnings last quarter?
Tsubota Laboratory Incorporated released its earnings results on Feb 13, 2026. The company reported -¥7.22 earnings per share for the quarter, missing the consensus estimate of N/A by -¥7.22.
Is Tsubota Laboratory Incorporated overvalued?
According to Wall Street analysts Tsubota Laboratory Incorporated’s price is currently Overvalued.
Does Tsubota Laboratory Incorporated pay dividends?
Tsubota Laboratory Incorporated does not currently pay dividends.
What is Tsubota Laboratory Incorporated’s EPS estimate?
Tsubota Laboratory Incorporated’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tsubota Laboratory Incorporated have?
Tsubota Laboratory Incorporated has 25,794,300 shares outstanding.
What happened to Tsubota Laboratory Incorporated’s price movement after its last earnings report?
Tsubota Laboratory Incorporated reported an EPS of -¥7.22 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.534%.
Which hedge fund is a major shareholder of Tsubota Laboratory Incorporated?
Currently, no hedge funds are holding shares in JP:4890
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tsubota Laboratory Incorporated
Tsubota Laboratory Incorporated engages in the research and development of pharmaceuticals and medical devices for the treatment of myopia, dry eyes, and presbyopia. The company was incorporated in 2012 and is based in Tokyo, Japan.
Technical Analysis
Sundrug Co
―
Sugi Holdings Co
―
TSURUHA Holdings
―
COSMOS Pharmaceutical Corporation
―
KUSURI NO AOKI HOLDINGS CO.,LTD.
―